Inhibitex Stock up 150% in Pre-Market (BMY, INHX)

Photo of Paul Ausick
By Paul Ausick Published

Bristol-Myers Squibb (NYSE: BMY) will pay $2.5 billion in cash (a 163% premium to Friday’s closing price) for hepatitis C drug developer Inhitibex Inc. (NASDAQ: INHX).

Contact [email protected] for any questions or corrections.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Top Gaining Stocks

DG Vol: 982,176
CAG Vol: 3,081,751
MOS Vol: 2,000,593
LYB Vol: 772,870
Dow
DOW Vol: 2,228,405

Top Losing Stocks

CTRA Vol: 73,319,495
WDC Vol: 1,398,087
STX Vol: 866,696
TDG Vol: 132,325
MU Vol: 11,636,510